|
DYRK1A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
4.3893000345463E-10 |
| Normal-vs-Stage3 |
2.22044604925031E-16 |
| Normal-vs-Stage4 |
2.44249065417534E-15 |
| Stage1-vs-Stage2 |
7.053800E-01 |
| Stage1-vs-Stage3 |
2.370100E-02 |
| Stage1-vs-Stage4 |
3.935700E-03 |
| Stage2-vs-Stage3 |
2.496200E-01 |
| Stage2-vs-Stage4 |
8.411600E-02 |
| Stage3-vs-Stage4 |
4.608600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
5.69750000000147E-05 |
| Normal-vs-Asian |
1.05849995435392E-10 |
| Caucasian-vs-AfricanAmerican |
1.119820E-01 |
| Caucasian-vs-Asian |
4.661200E-01 |
| AfricanAmerican-vs-Asian |
3.476600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.33066907387547E-16 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
9.325000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62614366416847E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
1.62481139653892E-12 |
| Normal-vs-Age(81-100Yrs) |
1.158200E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.636040E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.124400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.177800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.682000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.466600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.022200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.795580E-03 |
| Classical-VS-Follicular |
4.116400E-01 |
| Classical-VS-Other |
6.662800E-01 |
| Classical-VS-Normal |
2.37999620011919E-11 |
| Tall-VS-Follicular |
3.616000E-02 |
| Tall-VS-Other |
3.047400E-01 |
| Tall-VS-Normal |
7.69384556065233E-14 |
| Follicular-VS-Other |
8.950800E-01 |
| Follicular-VS-Normal |
4.99489338778858E-12 |
| Other-VS-Normal |
1.157670E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
9.31810184567894E-13 |
| N0-vs-N1 |
3.952200E-01 |
|
|
